The dual GIP/GLP-1 agonist class is the one that validated dual agonism. By engaging both the GIP and GLP-1 receptors with a single engineered peptide, it outperformed the single-receptor compounds that preceded it and reset expectations for what incretin-based design could achieve. This overview covers the second incretin hormone, how one peptide was built to activate two receptors, what the research shows, and the questions the class opened up.
The Second Incretin
Glucose-dependent insulinotropic polypeptide (GIP) is a 42-residue hormone released from K-cells in the upper small intestine in response to fat and carbohydrate. Historically it was the first incretin discovered, and in healthy physiology it accounts for the larger share of the incretin effect, the amplification of insulin release that happens when glucose arrives by mouth rather than by vein. Its receptor, GIPR, is a class B G-protein-coupled receptor on beta cells, in endocrine tissue, bone, and brain.
GIP fell out of favor as a research target for two decades because its insulin-boosting effect is blunted in metabolic disease and because, in endocrine tissue, it promotes fat storage. The dual-agonist class revived interest by showing that GIPR activation layered on top of GLP-1R activation produced effects neither achieved alone, which forced a reassessment of what GIP actually does.
The Mechanism
The leading dual agonist is a 39-amino-acid peptide built on the GIP backbone, with substitutions borrowed from GLP-1 and from exendin-4 that give it activity at the GLP-1 receptor while keeping GIP receptor activity, an Aib residue at position 2 for DPP-4 resistance, and a C20 fatty diacid on a lysine at position 20 for albumin binding and a week-scale half-life. Notably, its receptor balance is asymmetric: it binds GIPR with affinity similar to native GIP but GLP-1R with several-fold lower affinity than native GLP-1. That imbalance itself became a research topic. Understanding why a GIP-weighted dual agonist performs as it does has driven substantial receptor pharmacology work, including the discovery that the compound is a biased GLP-1R agonist, favoring cyclic AMP signaling over β-arrestin recruitment, which may reduce receptor desensitization.
What the Published Research Shows
Preclinical studies in rodent models showed that the dual agonist reduced feeding-pathway and metabolic more than a matched GLP-1 agonist, and that the extra effect was lost in GIPR-knockout animals, confirming the GIP arm contributed. Studies in endocrine tissue reported improved insulin sensitivity and changes in lipid handling attributed to GIPR. The clinical literature reported glycemic-control and weight results exceeding single GLP-1 agonists, which drove substantial follow-on receptor pharmacology work.
For the research field, the significance was conceptual: incretin receptors interact synergistically, and multi-receptor design became the default direction, leading directly to the triple incretin agonists.
The GIP Paradox
The class left the field with an unresolved puzzle. GIPR agonism improves metabolic outcomes in the dual agonist, yet GIPR antagonism and GIPR knockout also improve metabolic outcomes in rodent models, and an antibody that blocks GIPR while activating GLP-1R is in development. Both activating and blocking the same receptor appear to help. Leading explanations include receptor desensitization (chronic agonism may functionally resemble antagonism), differing roles of GIPR in brain versus fat, and species differences between rodent and human GIP biology. This is one of the most active questions in incretin research and a natural target for mechanistic laboratory work.
Studying the Dual Agonist Class
Laboratories use dual-agonist compounds in receptor cross-talk studies (how co-activation of GIPR and GLP-1R changes downstream signaling in cells expressing both), GIP-versus-GLP-1 contribution analyses (dual agonist against single agonist, with selective antagonists or knockout cells to isolate each arm), and as the middle arm in generational comparisons. In-vitro receptor panels measuring cAMP accumulation and β-arrestin recruitment at each receptor are the standard characterization. Because the compound’s GLP-1R potency is deliberately lower than a pure GLP-1 agonist’s, dose-matching across arms requires care: matching by GLP-1R activity gives a different comparison from matching by mass.
Handling Notes
As a 39-residue acylated peptide, the dual agonist shares the handling profile of the class: reconstitute gently in bacteriostatic water, do not shake, use low-binding tubes for dilute solutions, refrigerate, and protect from light (the sequence contains tryptophan and tyrosine). No methionine or cysteine. A Certificate of Analysis should confirm a mass near 4,813 Da and HPLC purity of 99% or better; with a sequence this long, deletion impurities are the main risk and may have their own receptor profiles (see Understanding Peptide Purity). Our guide to storage applies.
Research-Class Material
GLP2-T is our research-class dual agonist modeled on this class, third-party tested to 99%+ purity with COA documentation, alongside its single-agonist and triple-agonist counterparts in the Metabolic Research collection. The three generations are mapped in Single, Dual, and Triple Receptor Agonists Explained, and the amylin pathway that is often studied alongside them in Cagrilintide and the Amylin Pathway.
All products referenced are intended strictly for in-vitro research and laboratory use only. They are not for human or veterinary use, consumption, or therapeutic application.



